Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine

Charles Brindley, Andreas Gescher, Simon P. Langdon, Massimo Broggini, Tina Colombo, Maurizio D'incalci

Research output: Contribution to journalArticlepeer-review

Abstract

There is good evidence that the antitumour agent hexamethylmelamine (HMM) undergoes oxidative metabolic activation which might occur in the liver and/or extrahepatically. The hepatic microsomal N-methylmelamine metabolizing enzymes were investigated in mice and exhibited different affinities for different melamine derivatives. The apparent Km values are 0.09 mM for HMM, 0.23 mM for pentamethylmelamine, 0.91 mM for 2,2,4,6-tetramethylmelamine and 1.7 mM for trimethylmela-mine. HMM inhibited its own metabolism in vitro at substrate concentrations > 0.5 mM. Its hepatic microsomal N-demethylation rate was reduced when the mice were pretreated with the hepatic gluta-thione depleting agent methyliodide. Injection of hexaethylmelamine, a derivative of HMM without antineoplastic properties against the M5076 sarcoma in mice, lead to plasma concentrations of drug and metabolite pentaethylmelainine which were only a fraction of the drug and metabolite levels achieved after a similar dose of HMM.

Original languageEnglish
Pages (from-to)625-631
Number of pages7
JournalBiochemical Pharmacology
Volume31
Issue number5
DOIs
Publication statusPublished - Mar 1 1982

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine'. Together they form a unique fingerprint.

Cite this